Applied Nutrition expands manufacturing as revenue reaches £161.6m

Applied Nutrition expands manufacturing as revenue reaches £161.6m

Applied Nutrition is increasing manufacturing capacity following strong annual growth. FY26 revenue rose 50.9% to £161.6m, with a UK factory extension due before Christmas and new distribution infrastructure planned for the following financial year.


IN Brief:

  • Applied Nutrition reported FY26 revenue of £161.6m, up 50.9%, and adjusted EBITDA of £43.3m in unaudited preliminary results.
  • Its UK factory extension is expected before Christmas, with completed UK capacity described as capable of supporting approximately £300m in annual revenue.
  • The company expects about £205m revenue in FY27 but anticipates margin pressure from higher whey protein costs and a larger US contribution.

Applied Nutrition is expanding manufacturing and distribution capacity after annual revenue increased 50.9% to £161.6m, with its UK factory extension expected to be completed before Christmas. The sports nutrition and wellness producer reported further investment in automation, additional production facilities, and its recently acquired US manufacturing operation in results for the financial year ended 31 July 2026.

Unaudited preliminary figures published on 16 November show revenue rising from £107.1m to £161.6m and adjusted earnings before interest, tax, depreciation, and amortisation increasing 40.1% to £43.3m. Statutory profit before tax reached £41.0m, up from £28.5m. The figures reflect new products, broader distribution, and growth across the company’s principal markets.

Investment in manufacturing and logistics is accompanying the expanding product range. Applied Nutrition started developing an extension to its UK production operation during FY26, alongside a global distribution centre and head office. Management estimates that the completed UK manufacturing facilities could support approximately £300m in annual revenue. That is an estimate of production capacity expressed in revenue terms, not current sales, committed orders, or a forecast that the full amount will be achieved.

Completion of the UK factory extension is expected before Christmas 2026. The separate distribution centre and head office are scheduled to become operational during the second half of FY27, the financial year ending 31 July 2027. Those timelines concern different facilities, and finishing the production extension will not necessarily mean that the distribution development is ready for use.

Capital expenditure expectations for FY27 include about £4m for the distribution centre and head office, and £2.5m for continuing manufacturing investment. The latter covers completion of additional UK production facilities and efficiency improvements at the US operation. During FY26, spending on acquired tangible and intangible fixed assets, excluding the acquisition, totalled £2.0m, largely related to UK production facilities.

Automation investment is continuing within existing production operations, according to management, as the business seeks more consistent processes and productivity. The preliminary results do not identify specific suppliers, line rates, or detailed equipment specifications. Its revenue-based capacity estimate therefore cannot reliably be translated into tonnes of powder, packaged supplement units, or servings without the product mix and operating parameters.

The manufacturing network supports formulation, processing, and packaging for products including protein powders, pre-workout formulations, hydration products, and dietary supplements. Changes in ingredients and pack formats can affect dosing, blending, filling, and cleaning schedules. Increasing available factory space will only translate into useful output when these process requirements can be coordinated with the expanded product range and customer orders.

Inventory has risen sharply alongside sales and production activity. At 31 July 2026, the group held £44.5m of stock against £22.8m a year earlier; finished products and goods for resale accounted for £27.9m, compared with £10.0m. Larger stock holdings can help serve demand across more markets, but they also tie up working capital while the manufacturing and distribution network is expanding.

The June purchase of Nutrablend’s trade and substantially all of its assets added manufacturing and warehousing capability in the United States. Applied Nutrition paid approximately £12m in cash for the operation and expects a local production base to shorten customer lead times while easing some demand on UK capacity. It has not disclosed the volume of production that will ultimately move between the two countries.

Revenue growth was spread across regions. UK sales increased 45.2% to £70.3m, European sales rose 34.0% to £20.9m, and the rest of the world contributed £70.4m, an increase of 63.3%. The US acquisition contributed £1.6m of revenue during FY26, leaving reported organic group revenue growth at 49.4%.

Business-to-business sales dominate the group’s distribution model. They reached £146.9m in FY26 against £14.7m from direct-to-consumer activity. The reliance on commercial distribution partners makes manufacturing capacity, stock availability, and delivery performance important operating requirements as the company introduces more formulations and pack sizes.

Protein products contributed £53.2m of reported revenue, compared with £32.0m in FY25. The company also recorded £28.3m in its intra-workout category, £27.2m in grab-and-go, and £25.8m in health and wellness. Management reported a 142% increase in sales of the relaunched Critical Whey range, following reformulation and product changes.

Higher whey protein input costs are expected to reduce the FY27 adjusted EBITDA margin slightly against FY26, according to management. The company also expects a higher share of whey-based products and a larger US contribution, where margins are lower. Although whey prices have eased recently, Applied Nutrition expects its average cost of whey consumed during FY27 to remain above the previous year’s level.

Raw material price movements affect production planning well before a finished pack is sold. Protein specifications, supply agreements, and stock already purchased determine the cost entering a production run, while the final selling price depends on the customer channel and product. Applied Nutrition has increased selling prices to offset some of the expected cost pressure, but that does not eliminate the effect on margins or inventory financing.

Free cash flow declined to £10.6m from £16.5m, while year-end net cash excluding lease liabilities stood at £15.9m. The company expects working capital requirements to rise further in the first half of FY27 as it rebuilds inventory and operating resources at the US business. Those demands sit alongside the planned spend on factory and distribution capacity.

Management continues to guide for approximately £205m in FY27 revenue and £49m of adjusted EBITDA, even after a strong first quarter. Completion of the UK factory extension before Christmas and the later opening of the distribution facility are the next stated operational milestones. Actual use of the enlarged manufacturing capacity will depend on demand, product mix, ingredient supply, and the efficiency of both the UK and US operations.


Stories for you


  • Applied Nutrition expands manufacturing as revenue reaches £161.6m

    Applied Nutrition expands manufacturing as revenue reaches £161.6m

    Applied Nutrition is increasing manufacturing capacity following strong annual growth. FY26 revenue rose 50.9% to £161.6m, with a UK factory extension due before Christmas and new distribution infrastructure planned for the following financial year.


  • Coffee King tenders for Deeside roasting equipment

    Coffee King tenders for Deeside roasting equipment

    Coffee King is seeking suppliers for expanded Deeside production operations. Its 16 November tender specifies coffee roasters, bean handling, packaging and bakery equipment, with quotations due at noon on 20 November.